In:
Blood Advances, American Society of Hematology, Vol. 1, No. 26 ( 2017-12-12), p. 2541-2552
Abstract:
CML patients can be stratified into 4 subgroups with different risk of blastic transformation based on cytogenetic abnormalities. TKI therapy mitigates risk of blastic transformation associated with low-risk ACAs or no ACAs but not that associated with HR ACAs.
Type of Medium:
Online Resource
ISSN:
2473-9529
,
2473-9537
DOI:
10.1182/bloodadvances.2017011858
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2017
detail.hit.zdb_id:
2876449-3
detail.hit.zdb_id:
2915908-8
Permalink